The Egyptian Journal of Internal Medicine (Jul 2022)

Micro-elimination of hepatitis C in patients with chronic kidney disease: an Egyptian single-center study

  • Tari George Michael,
  • Christina A. Anwar,
  • Ossama A. Ahmed,
  • Iman Sarhan,
  • Yehia Elshazly,
  • Mohammed K. Shaker,
  • Mohammed Eltabbakh,
  • Walaa Hashem,
  • Safaa R. Tawfic,
  • Shimaa Y. Kamel,
  • Doaa M. Kandil,
  • Gina G. Naguib,
  • Abdelrahman Khedr,
  • Eman A. Ghanem,
  • Hany Dabbous,
  • Wahid Doss,
  • Manal H. El-Sayed

DOI
https://doi.org/10.1186/s43162-022-00139-3
Journal volume & issue
Vol. 34, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Background and aims Micro-elimination of hepatitis C in renal patients is crucial. This study aims to assess the efficacy and safety of directly acting antivirals in chronic kidney disease patients and the effect of treatment on kidney functions. Results This prospective cohort study included 77 chronic HCV-infected patients with chronic kidney disease. Patients were consented and treated for 12 weeks with either sofosbuvir and daclatasvir ± ribavirin if glomerular filtration rate was > 30 mL/min per 1.73m2 or ritonavir-boosted paritaprevir-ombitasvir-ribavirin if it was < 30 mL/min per 1.73m2. Patients were divided into two categories (responders versus non-responders). Predictors of response to treatment were statistically analyzed through logistic regression analysis. Sixty-two patients received ritonavir-boosted paritaprevir-ombitasvir-ribavirin, 3 received sofosbuvir and daclatasvir, and 12 received sofosbuvir and daclatasvir plus ribavirin. Most patients were on hemodialysis (n = 36) while 31 were stage 3 kidney disease. All patients completed their treatment course; ribavirin doses were adjusted or stopped in patients who developed anemia (40%). Seventy-two patients (93.5%) achieved sustained virological response 12 weeks following end-of-treatment. Five patients (6.5%) were non-responders, 4 of whom were on hemodialysis (p = 0.179). All non-responders were on ritonavir-boosted paritaprevir-ombitasvir-ribavirin. The mean serum creatinine level at weeks 4 and 8 of treatment demonstrated significant improvement compared to pretreatment values (p < 0.001) in patients on conservative therapy. Conclusion Treatment of chronic kidney disease patients for chronic hepatitis C with directly acting antivirals is safe, efficacious with high response rates and likely to improve renal functions if started early in the course of kidney disease.

Keywords